SCHEMBL3368155

SCHEMBL3368155

CC/C=C\CC(O)/C=C/C1C(=O)C[C@H](O)C1C/C=C\CCCC(=O)O

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.75
PTGDR2 Q9Y5Y4 3/20 0.75
SLCO2A1 Q92959 2/20 0.75
PTGFR P43088 4/20 0.53
PTGER4 P35408 3/20 0.53
PTGER3 P43115 3/20 0.53
PTGER2 P43116 2/20 0.53
PTGIR P43119 2/20 0.53
TBXA2R P21731 2/20 0.53
PTGER1 P34995 2/20 0.53
NR1I2 O75469 1/20 0.53
ESR1 P03372 1/20 0.53
PGR P06401 1/20 0.53
HPGD P15428 1/20 0.53
TSHR P16473 1/20 0.53
MAPK1 P28482 1/20 0.53
OPRK1 P41145 1/20 0.53
PDE4D Q08499 1/20 0.53
LMNA P02545 1/20 0.48
PTGDR Q13258 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25608108 1.00 ALDH1A1 (0.75) ALDH1A1PTGDR2SLCO2A1PTGFRPTGER4
SCHEMBL20613688 1.00 ALDH1A1 (0.75) ALDH1A1PTGDR2SLCO2A1PTGFRPTGER4
SCHEMBL25608037 1.00 ALDH1A1 (0.75) ALDH1A1PTGDR2SLCO2A1PTGFRPTGER4
SCHEMBL13649330 1.00 ALDH1A1 (0.75) ALDH1A1PTGDR2SLCO2A1PTGFRPTGER4
SCHEMBL29391375 0.91 ALDH1A1 (0.62) ALDH1A1PTGDR2SLCO2A1PTGFRPTGER4
[3H]Pgd2 SCHEMBL23352891 0.86 ALDH1A1 (1.00) ALDH1A1PTGDR2SLCO2A1PTGFRPTGER4
[3H]Pgd2 SCHEMBL22425683 0.86 ALDH1A1 (1.00) ALDH1A1PTGDR2SLCO2A1PTGFRPTGER4
[3H]Pgd2 SCHEMBL13260237 0.86 ALDH1A1 (1.00) ALDH1A1PTGDR2SLCO2A1PTGFRPTGER4
[3H]Pgd2 SCHEMBL22425684 0.86 ALDH1A1 (1.00) ALDH1A1PTGDR2SLCO2A1PTGFRPTGER4
[3H]Pgd2 SCHEMBL13399729 0.86 ALDH1A1 (1.00) ALDH1A1PTGDR2SLCO2A1PTGFRPTGER4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2349242-B1 AMINO ACID SALTS OF PROSTAGLANDINS NOVAER HOLDINGS INC (US) 2018-12-05 EP disclosed
EP-3195857-A1 USE OF A TRP MODULATOR FOR THE PROPHYLAXIS AND/OR ALLEVIATING OF GRASS TETANY AND/OR PARTURIENT PARESIS IN TYLOPODA OR RUMINANTS Freie Universität Berlin (DE) 2017-07-26 EP disclosed
US-9693971-B2 Compositions for alleviating gastrointestinal tract disorders or associated systemic disorders in ruminants and camelids FREIE UNIVERSITÄT BERLIN (DE) 2017-07-04 US disclosed
EP-2879662-B1 COMPOSITION FOR ALLEVIATING GASTROINTESTINAL DEFECTS OR SYSTEMIC SYMPTOMES ASSOCIATED HEREWITH IN RUMINANTS AND CAMELIDS FREIE UNIVERSITÄT BERLIN (DE) 2017-02-08 EP disclosed
US-20150164822-A1 COMPOSITIONS FOR ALLEVIATING GASTROINTESTINAL TRACT DISORDERS OR ASSOCIATED SYSTEMIC DISORDERS IN RUMINANTS AND CAMELIDS PERFORMANAT GMBH (DE) 2015-06-18 US disclosed
EP-2879662-A1 COMPOSITIONS FOR ALLEVIATING GASTROINTESTINAL TRACT DISORDERS OR ASSOCIATED SYSTEMIC DISORDERS IN RUMINANTS AND CAMELIDS Freie Universität Berlin (DE) 2015-06-10 EP disclosed
US-8722739-B2 Amino acid salts of prostaglandins NOVAER HOLDINGS, INC. (US) 2014-05-13 US disclosed
WO-2014020067-A1 COMPOSITIONS FOR ALLEVIATING GASTROINTESTINAL TRACT DISORDERS OR ASSOCIATED SYSTEMIC DISORDERS IN RUMINANTS AND CAMELIDS FREIE UNIVERSITÄT BERLIN (DE) 2014-02-06 WO disclosed
US-20140031423-A1 AMINO ACID SALTS OF PROSTAGLANDINS NOVAER HOLDINGS, INC. (US) 2014-01-30 US disclosed
US-8623918-B2 Amino acid salts of prostaglandins NOVAER HOLDINGS, INC. (US) 2014-01-07 US disclosed
US-8470882-B2 2013-06-25 US disclosed
US-20100105771-A1 AMINO ACID SALTS OF PROSTAGLANDINS NOVAER HOLDINGS, INC. 2010-04-29 US disclosed
US-20100105775-A1 AMINO ACID SALTS OF PROSTAGLANDINS NOVAER HOLDINGS, INC. 2010-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105771-A1 AMINO ACID SALTS OF PROSTAGLANDINS PTGIS, PTGES, PTGIR ALDH1A1 3538/4885PTGDR2 10/4885SLCO2A1 1547/4885
US-20100105775-A1 AMINO ACID SALTS OF PROSTAGLANDINS PTGIS, PTGES, PTGIR ALDH1A1 3538/4885PTGDR2 10/4885SLCO2A1 1547/4885
US-20140031423-A1 AMINO ACID SALTS OF PROSTAGLANDINS PTGIS, PTGES, PTGIR ALDH1A1 3538/4885PTGDR2 10/4885SLCO2A1 1547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.